stockportfolio.pro
BBIO vs RVTY: Which Stock Is the Better Buy?
BridgeBio Pharma, Inc. and Revvity, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — BBIO vs RVTY, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| BridgeBio Pharma, Inc. (BBIO) | Revvity, Inc. (RVTY) | |
|---|---|---|
| Market cap | $13.3B | $12.7B |
| Revenue (latest FY) | $502.08M | $2.86B |
| Net income (latest FY) | $-724.93M | $241.20M |
| Revenue growth (5y CAGR) | 127.4% | -5.5% |
| Net margin | -144.4% | 8.4% |
| Return on equity | 34.7% | 3.3% |
| P/E ratio | — | 54.7 |
| Dividend yield | — | 0.3% |
| Profitable years (of last 10) | 0 | 10 |
| Positive free cash flow | No | Yes |
See the full BBIO vs RVTY breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open BBIO's full financials → Open RVTY's full financials →More comparisons
Frequently asked questions
Which is bigger, BBIO or RVTY?
BridgeBio Pharma, Inc. is larger by market capitalization — $13.3B versus $12.7B.
Which grows faster, BBIO or RVTY?
Over the last five fiscal years, BridgeBio Pharma, Inc. grew revenue faster — 127.4%/yr versus -5.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.